CTNM (STOCKS)
Contineum Therapeutics, Inc. Class A Common Stock
$12.760000
-0.110000 (-0.85%)
Prev close: $12.870000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Carmine N. Stengone
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $493.76M
- Employees
- 41
- P/E (TTM)
- -5.84
- P/B (TTM)
- 1.84
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $8.08M |
| Operating Expenses | $68.06M |
| Research and Development | $51.52M |
| Other Operating Expenses | $16.54M |
| Operating Income/Loss | -$68.06M |
| Income/Loss From Continuing Operations After Tax | -$60.14M |
| Income/Loss From Continuing Operations Before Tax | -$60.14M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$59.98M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$59.98M |
| Net Income/Loss Available To Common Stockholders, Basic | -$59.98M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.17 |
| Diluted Earnings Per Share | -$2.17 |
| Basic Average Shares | 27,700,855 |
| Diluted Average Shares | 27,700,855 |
| Assets | $276.64M |
| Current Assets | $267.92M |
| Cash | $262.90M |
| Other Current Assets | $5.02M |
| Noncurrent Assets | $8.73M |
| Fixed Assets | $830.00K |
| Other Non-current Assets | $7.90M |
| Liabilities | $15.65M |
| Current Liabilities | $9.74M |
| Accounts Payable | $1.02M |
| Wages | $4.80M |
| Other Current Liabilities | $3.93M |
| Noncurrent Liabilities | $5.91M |
| Equity | $260.99M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $260.99M |
| Liabilities And Equity | $276.64M |
| Net Cash Flow From Operating Activities | -$55.31M |
| Net Cash Flow From Operating Activities, Continuing | -$55.31M |
| Net Cash Flow From Investing Activities | -$3.71M |
| Net Cash Flow From Investing Activities, Continuing | -$3.71M |
| Net Cash Flow From Financing Activities | $112.69M |
| Net Cash Flow From Financing Activities, Continuing | $112.69M |
| Net Cash Flow | $53.66M |
| Net Cash Flow, Continuing | $53.66M |
| Comprehensive Income/Loss | -$59.79M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$59.79M |
| Other Comprehensive Income/Loss | -$59.79M |